--- title: "【XtalPi · Longbridge Wiki】Key Facts and Resource Navigation (Pinned/Co-Updated)" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/33612149.md" description: "I'll create a template first, but it's unclear whether it can be maintained long-term. There's no established plan or practice for long-term maintenance yet. I just think this approach is meaningful. The implementation of a community co-building model also needs exploration. I'll post this long thread first. If you have ideas on how to maintain this "Frontpage," please share them in the comments below. If a final version is decided later, I plan to advance this by maintaining an email list. Aim to have a clear conclusion by next weekend..." datetime: "2025-09-04T01:41:51.000Z" locales: - [en](https://longbridge.com/en/topics/33612149.md) - [zh-CN](https://longbridge.com/zh-CN/topics/33612149.md) - [zh-HK](https://longbridge.com/zh-HK/topics/33612149.md) author: "[老板的老板 AI Exec](https://longbridge.com/en/profiles/123.md)" --- # 【XtalPi · Longbridge Wiki】Key Facts and Resource Navigation (Pinned/Co-Updated) > I'm creating a template, but it's unclear whether it can be maintained long-term. There's no established plan or practice for long-term maintenance yet. I just think this approach is meaningful. The implementation of a community co-construction model also needs exploration. I'm posting this long thread first. If you have ideas on how to maintain this "Frontpage," please share them in the comments below. If a final version is agreed upon, I plan to advance this initiative through maintaining an email list. Aiming to reach a clear conclusion by next weekend. > **Positioning**: A "Frontpage" for investors of $XTALPI(02228.HK), exclusively featuring **publicly available and verifiable definitive information** (based on company announcements/prospectuses/annual reports). > **Co-construction method**: Reply with "\[Correction/Addition\] + Brief description + Official source link/announcement number." Moderators will consolidate these into the main post weekly. > **Update frequency**: Rolling updates (weekly or ad-hoc for major announcements). > **Scope**: Avoid discussions on stock prices, valuations, K-lines, etc. Focus on **business, technology, milestones, governance, and disclosures**. * * * ## Table of Contents [Quick Facts (Factsheet)](#%E4%B8%80%E9%A1%B5%E9%80%9F%E8%A7%88factsheet) [Business and Technology Stack](#%E4%B8%9A%E5%8A%A1%E4%B8%8E%E6%8A%80%E6%9C%AF%E6%A0%88) [Client and Partnership Milestones (Timeline)](#%E5%AE%A2%E6%88%B7%E4%B8%8E%E5%90%88%E4%BD%9C%E9%87%8C%E7%A8%8B%E7%A2%91%E6%97%B6%E9%97%B4%E7%BA%BF) [Shareholding Structure and Major Shareholders (Dynamic)](#%E8%82%A1%E6%9D%83%E7%BB%93%E6%9E%84%E4%B8%8E%E4%B8%BB%E8%A6%81%E8%82%A1%E4%B8%9C%E5%8A%A8%E6%80%81) [Announcements and Disclosure Portal](#%E5%85%AC%E5%91%8A%E4%B8%8E%E6%8A%AB%E9%9C%B2%E5%85%A5%E5%8F%A3) [Frequently Used Links and External Information](#%E5%B8%B8%E7%94%A8%E9%93%BE%E6%8E%A5%E4%B8%8E%E5%AF%B9%E5%A4%96%E4%BF%A1%E6%81%AF) [FAQ (For Newcomers)](#faq%E9%9D%A2%E5%90%91%E6%96%B0%E6%9C%8B%E5%8F%8B) [Co-construction List (Pending Updates/Verification)](#%E5%85%B1%E5%BB%BA%E6%B8%85%E5%8D%95%E5%BE%85%E8%A1%A5%E5%BE%85%E6%A0%B8) [Update Log](#%E6%9B%B4%E6%96%B0%E6%97%A5%E5%BF%97) * * * ## Quick Facts (Factsheet) Item Content **Company** XtalPi Holdings Limited (**XtalPi Holdings Limited**; HKEX: **02228**)[etnet](https://www.etnet.com.hk/www/eng/stocks/realtime/quote_ci_brief.php?code=2228&utm_source=chatgpt.com) **Listing** Hong Kong Stock Exchange Main Board; **Listing Date: 2024-06-13** (Prospectus/Exchange Materials)[Moomoo](https://www.moomoo.com/stock/02228-HK/company?utm_source=chatgpt.com)[ir.xtalpi.com](https://ir.xtalpi.com/media/hmtn0mw1/2024060400065.pdf?utm_source=chatgpt.com) **Positioning** A **"Quantum Physics + Artificial Intelligence + Robotic Automation"**\-driven **drug and materials R&D platform** (AI4Science)[ir.xtalpi.com](https://ir.xtalpi.com/media/1sxbieyn/2025040702143.pdf?utm_source=chatgpt.com)[XtalPi](https://en.xtalpi.com/technology/?utm_source=chatgpt.com) > Note: This table only includes **definitive, verifiable** "framework information." In case of discrepancies, the **announcements/prospectuses/annual reports** shall prevail. * * * ## Business and Technology Stack **Methodological Integration**: A hybrid R&D engine combining **first-principles/quantum mechanics calculations (QM) + machine learning (AI) + high-performance computing + robotic automation**, aiming to **enhance the throughput and accuracy of candidate molecule design and validation**.[ir.xtalpi.com](https://ir.xtalpi.com/media/1sxbieyn/2025040702143.pdf?utm_source=chatgpt.com)[XtalPi](https://en.xtalpi.com/technology/?utm_source=chatgpt.com) **Platform Products** **ID4Inno™** (End-to-end small molecule discovery): Rapidly constructs "vast chemical spaces" for specific targets, converging to the most promising lead series, and validates through automated experimental closed-loop iterations.[XtalPi](https://en.xtalpi.com/xtalpi-announces-collaboration-with-lilly-using-ai-robotics-to-uncover-first-in-class-therapeutics/?utm_source=chatgpt.com) **XFEP** (Free Energy Perturbation/FEP calculations): Enhances prediction accuracy for small molecule affinity and other properties, serving as a key capability in collaborations with major pharmaceutical companies.[World Pharmaceutical Frontiers](https://www.worldpharmaceuticals.net/news/xtalpi-pfizer-expand-drug-discovery-collaboration/?utm_source=chatgpt.com) **Automated Laboratories**: Scalable and standardized synthesis, characterization, and bioassay capabilities, forming a closed-loop of "**AI ↔ Robotics**" data integration.[XtalPi](https://en.xtalpi.com/technology/?utm_source=chatgpt.com) **Applications**: Accelerates key stages from **target validation, molecule generation, affinity prediction, ADMET assessment, to synthesis route design** (per prospectus/annual report).[ir.xtalpi.com](https://ir.xtalpi.com/media/1sxbieyn/2025040702143.pdf?utm_source=chatgpt.com) * * * ## Client and Partnership Milestones (Timeline) > Only includes **publicly verifiable information**. The community is encouraged to **supplement** additional partnership events (with sources). **2025-06-29**｜**Expanded Strategic Collaboration with Pfizer**: Jointly develop a higher-throughput prediction platform to cover Pfizer's expanding small molecule chemical space, deploying tools like XFEP (press release/industry media).[prnewswire.com](https://www.prnewswire.com/news-releases/xtalpi-and-pfizer-expand-strategic-collaboration-to-advance-ai-driven-drug-discovery-and-materials-science-simulations-302494033.html?utm_source=chatgpt.com)[fiercebiotech.com](https://www.fiercebiotech.com/biotech/pfizer-expands-ai-powered-small-molecule-discovery-collab-xtalpi?utm_source=chatgpt.com)[World Pharmaceutical Frontiers](https://www.worldpharmaceuticals.net/news/xtalpi-pfizer-expand-drug-discovery-collaboration/?utm_source=chatgpt.com) **2023-05-30/06-01**｜**Collaboration with Eli Lilly**: AI + robotics platform for de novo design and delivery of drug candidates, with **milestone payments up to $250 million** (PRNewswire/official news).[prnewswire.com](https://www.prnewswire.com/news-releases/xtalpi-announces-collaboration-with-lilly-using-ai--robotics-to-uncover-first-in-class-therapeutics-301837142.html?utm_source=chatgpt.com)[XtalPi](https://en.xtalpi.com/xtalpi-announces-collaboration-with-lilly-using-ai-robotics-to-uncover-first-in-class-therapeutics/?utm_source=chatgpt.com) **2020–Present**｜Collaboration with **Signet Therapeutics** and others on pioneering projects for novel targets like gastrointestinal cancer (per public news).[XtalPi](https://en.xtalpi.com/xtalpi-and-signet-expand-ai-drug-discovery-collaboration-to-novel-cancer-target/?utm_source=chatgpt.com) > Suggestions: Organize historical collaborations with **Janssen, UCB, A\*STAR, Lilly** into a "long table" with **timestamps** and **source references** for verification and cross-referencing (volunteers welcome). * * * ## Shareholding Structure and Major Shareholders (Dynamic) > This section is **updated dynamically per announcements**; refer to **HKEX disclosures/company annual & interim reports**. **Disclosed Major Shareholders/Key Holders (Example, for verification)** **WSH Family / TMF (Trust Platform)**, **5Y Capital (formerly Morningside/Sequoia-related platforms, per actual announcements)**, **Tencent**, **China Life Private Equity**, **Goldman Sachs**, **Sequoia China (HongShan-related platforms per disclosures)**, etc., appeared in 2025 third-party data platforms/disclosures (**refer to announcements & DI notices**).[MarketScreener](https://www.marketscreener.com/quote/stock/XTALPI-HOLDINGS-LIMITED-171054629/company-shareholders/?utm_source=chatgpt.com)[Investing.com](https://www.investing.com/equities/quantumpharm-ownership?utm_source=chatgpt.com)[di.hkex.com.hk](https://di.hkex.com.hk/di/NSConstdSSList.aspx?cid=0&cn=1&corpn=XtalPi+Holdings+Ltd.+-+P&ed=03%2F03%2F2025&lang=EN&sa1=cl&sa2=cs&sced=03%2F03%2F2025&scsd=03%2F03%2F2024&sd=03%2F03%2F2024&sid=467660&src=Main&srchCorpName=XtalPi+Holdings+Ltd.+-+P&utm_source=chatgpt.com) * * * ## Announcements and Disclosure Portal **Company Website · Investor Relations** (Financial reports, announcements, roadshow materials, prospectuses, etc.).[ir.xtalpi.com](https://ir.xtalpi.com/en/investor-relations/financial-reports/?utm_source=chatgpt.com) **HKEX Disclosures**: Prospectuses, periodic reports, placements/share changes, etc. (Bookmark the "Company Search" page).[hkexnews.hk](https://www.hkexnews.hk/listedco/listconews/sehk/2025/0827/2025082701123.pdf?utm_source=chatgpt.com)[www1.hkexnews.hk](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0219/2025021900053.pdf?utm_source=chatgpt.com) **Interim/Annual Reports (English Examples)**: **2024 Annual Report** (2025-04-07 release), **2025 Interim Results**, etc.[ir.xtalpi.com+1](https://ir.xtalpi.com/media/1sxbieyn/2025040702143.pdf?utm_source=chatgpt.com) * * * ## Frequently Used Links and External Information **Official Website & Technology Page**: Company positioning, platforms, and case studies (English).[XtalPi+1](https://en.xtalpi.com/?utm_source=chatgpt.com) **News Center**: Collaborations, M&A, and ecosystem updates (e.g., expanded Pfizer collaboration; LCC acquisition).[XtalPi](https://en.xtalpi.com/category/news/?utm_source=chatgpt.com) **Media Coverage**: FierceBiotech, WorldPharma, etc., on Pfizer's expanded collaboration.[fiercebiotech.com](https://www.fiercebiotech.com/biotech/pfizer-expands-ai-powered-small-molecule-discovery-collab-xtalpi?utm_source=chatgpt.com)[World Pharmaceutical Frontiers](https://www.worldpharmaceuticals.net/news/xtalpi-pfizer-expand-drug-discovery-collaboration/?utm_source=chatgpt.com) * * * ## FAQ (For Newcomers) **Q1: What does XtalPi do?** A: A **"platform company"** for **drug and materials R&D** using **AI+QM+automation**—providing **R&D services/solutions** while gradually expanding into **joint development/milestone collaborations** (see website/annual report).[ir.xtalpi.com](https://ir.xtalpi.com/media/1sxbieyn/2025040702143.pdf?utm_source=chatgpt.com) **Q2: What are its flagship platforms?** A: **ID4Inno™** (small molecule discovery), **XFEP** (FEP calculations), and scalable **automated laboratories**.[XtalPi+1](https://en.xtalpi.com/xtalpi-announces-collaboration-with-lilly-using-ai-robotics-to-uncover-first-in-class-therapeutics/?utm_source=chatgpt.com)[World Pharmaceutical Frontiers](https://www.worldpharmaceuticals.net/news/xtalpi-pfizer-expand-drug-discovery-collaboration/?utm_source=chatgpt.com) **Q3: Any notable "big pharma" collaborations?** A: Publicly verifiable ones include **Eli Lilly (2023)** and **Pfizer (2025 expansion)**; specifics subject to official announcements/press releases.[prnewswire.com+1](https://www.prnewswire.com/news-releases/xtalpi-announces-collaboration-with-lilly-using-ai--robotics-to-uncover-first-in-class-therapeutics-301837142.html?utm_source=chatgpt.com) * * * ## Co-construction List (Pending Updates/Verification) **Shareholder Structure Long Table**: Compare **pre-/post-latest placement** shareholder percentages in a "two-column format" (with announcement numbers). **Partnership Long Table**: Supplement **Janssen/UCB/A\*STAR** events with **dates, themes, and sources**. **Technical Whitepapers/Papers**: Select high-value entries on **methodology/platform validation** with **links + one-sentence summaries**. **Glossary**: Define **FEP, ID4Inno, ADMET, high-throughput automation** in **one sentence**. > **Volunteer Recruitment**: 3–4 volunteers to claim the above tasks; reply with "Claim + WeChat/email (DM acceptable)". * * * ## Update Log **v2025-09-03**: Created Frontpage; added Factsheet, tech stack, partnership milestones, and announcement portal; launched "Co-construction List." (Moderator: @you) * * * ### Notes and Acknowledgments All factual information here includes **clickable sources**. If discrepancies with **official announcements** are found, please comment with **authoritative links**. Revisions will be made within **24–72h**. Thanks to community members for corrections and additions (credits listed here). ### Related Stocks - [02228.HK](https://longbridge.com/en/quote/02228.HK.md) ## Comments (2) - **很发财 · 2025-09-04T02:58:49.000Z**: Today 📉 fell - **江汉南京 · 2025-09-04T01:43:41.000Z**: Thank you for sharing, boss.